This page is the continuation of references in support of Section 8a Breast Cancer Treatment.
REFERENCES
Beresford, M., Tumur, I., Chakrabarti, J., et al. (2011). A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol). 23(3), 209-15. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/books/NBK81846/
Blazeby, J.M,, Wilson, L., Metcalfe, C., Nicklin, J., English, R., Donovan, J.L (2006). Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol 17: 457–460. (Retrieved November 26th 2014): https://academic.oup.com/annonc/article/17/3/457/146245
Calman, K.C., Hine, J. (1995). A policy framework for commissioning cancer services. A report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, Department of Health: London 1995.
Cardoso, F., Bedard, P.L., Winer, E.P., et al. (2009). International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101, 1174-1181. (Retrieved November 26th 2014): https://academic.oup.com/jnci/article/101/17/1174/906807
Giordano, S.H., Buzdar, A.U., Smith, T.L., et al. (2004). Is breast cancer survival improving? Cancer 100(1), 44. (Retrieved November 26th 2014): https://www.ncbi.nlm.nih.gov/pubmed?term=14692023
Miller K,, Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–2676. (Retrieved November 27th 2014): https://www.nejm.org/doi/full/10.1056/NEJMoa072113
